|
Company Name: Orbis Research |
||
Founded: |
Annual Revenue: |
|
Exchange: 64101019 |
Emailwire ID: |
|
Number of Employees: |
Symbol: |
|
Categories: Consumer Research,Markets,... |
Press Releases
KOL Perspectives: Perceptions of Recent and Upcoming Data For Key Hbv Pipeline Agents
(EMAILWIRE.COM, December 06, 2018 ) This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents. Questions topics - - Further Phase I data required for Roche’s capsid inhibitor RO7049389 - Replicor’s US trial plans and transition from IV to subcutaneous...more
KOL Perspectives: Patient Niches in IBD
(EMAILWIRE.COM, December 06, 2018 ) This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD. Questions topics - - Perceptions on patient niches and treatments of fistulizing Crohn’s disease - Perceptions on patient niches and treatments in small-bowel Crohn’s disease - Perceptions...more
KOL Perspectives: Adaptive Trial Designs in IBD
(EMAILWIRE.COM, December 06, 2018 ) This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD. Questions topics - - Current challenges in IBD clinical trials - Adaptive Phase II/III trial designs - Guselkumab’s Phase II/III trial in Crohn’s disease - Novel clinical...more
KOL Perspectives: Histologic Healing in Crohns disease
(EMAILWIRE.COM, December 06, 2018 ) This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn’s disease. Questions topics - - Use of histological assessment in clinical trials and practice in Crohn’s disease - Extrapolation of UC histology to UC - Barriers to adoption...more
KOL Perspectives: Rituximab Use in Lupus
(EMAILWIRE.COM, December 06, 2018 ) Key Highlights - Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price - Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high...more